BrainCells Inc., the San Diego-based developer of treatments for neurological disorders, said today that its experimental drug for depression showed promising results in a clinical trial of 142 patients. The company’s drug, BCI-952, a combination of low-dose buspirone and melatonin, is designed to work differently than other depression drugs, by stimulating growth of new brain cells. The drug showed statistically significant results on some, but not all measurements of depression. Data were presented at NCDEU, a meeting co-sponsored by the National Institute of Mental Health and the American Society of Clinical Psychopharmacology.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
